Tryp Therapeutics is pursuing Phase 2 clinical trials using its psilocybin-based drug products for chronic pain and other indications.
Tryp’s pipeline differs from other psychedelic drug development companies in three important ways.
1. Unique Indications
The first wave of psychedelic drug development has been focused on mental health disorders such as depression, anxiety, addiction and PTSD.
As the leader in next-wave development, Tryp is evaluating psilocybin-based drug products for chronic pain and other indications with multiple Phase 2a trials initiating in 2021.
Tryp is one of just a handful of psychedelic drug development companies that will be conducting Phase 2 clinical trials in 2021.
2. A proprietary formulation and delivery method.
Our psilocybin-based drug product, TRP-8803, features a proprietary formulation and novel method of administration to improve the patient experience. We have filed a provisional patent to protect the unique features of TRP-8803.
3. An exclusive supply chain.
We’ve secured an exclusive supply of our psilocybin-based active ingredients and drug products, with sufficient quantities of material to support clinical trials and ultimate commercialization—a rare capability among psychedelic drug development companies.
As part of our Psilocybin For Neuropsychiatric Disorders (PFNTM) program, we’re currently testing two drugs for efficacy and patient experience: TRP-8802 and TRP-8803.
Our novel method of administration for TRP-8803 is expected to improve the patient experience. Our drug products are given in tandem with psychotherapy before and after drug treatment.
This non-proprietary 25 mg oral capsule of synthetic psilocybin will be used to determine initial efficacy of the drug product for our indications.
As Tryp Therapeutics is solely focused on psilocybin, and because more than 50 FDA-registered studies have firmly established the compound’s safety profile, we expect to bypass preclinical and Phase 1 studies and enter directly into Phase 2a clinical trials.
This proprietary, psilocybin-based drug is manufactured exclusively for Tryp by Curia and Alcami and features a novel route of administration.
We expect the proprietary formulation of TRP-8803 and its unique route of administration to improve the patient experience.
The need is clear. So is the solution.
A closer look at patient needs:
Phantom Limb Pain
Complex Regional Pain Syndrome (CRPS)
We’ve partnered with the Chronic Pain & Fatigue Research Center at the University of Michigan to advance our fibromyalgia studies—and we will be announcing partnerships for our clinical trials for phantom limb pain and complex regional pain syndrome soon.
Based on existing preclinical and clinical data for the active ingredients in TRP-8802, we anticipate FDA support to proceed directly into Phase 2 trials.
Download our white paper describing our rationale for the use of psychedelics for chronic pain here:Tryp Therapeutics White Paper on Chronic Pain
For millions of patients, relief can’t come soon enough.
A closer look at patient needs.
Binge Eating Disorder (BED)
Tryp is collaborating with Jennifer Miller, M.D. from the University of Florida’s Division of Pediatric Endocrinology to evaluate the efficacy of our drug products. Dr. Miller is a world-renowned expert in overeating disorders such as binge eating and hypothalamic obesity.
Based on the well-established safety profile of psilocybin, we expect to advance directly into Phase 2a clinical trials.
Download our white paper describing our rationale for the use of psychedelics for overeating disorders here:Tryp Therapeutics White Paper on Overeating Disorders
Tryp manufactures its own synthetic psilocybin—a unique asset among psychedelic drug development companies that gives us complete control over our product supply for clinical trials and ultimate commercialization.
You can expect excellence at every stage.
Current good manufacturing practice (cGMP)
Working at scale
We have established a unique manufacturing process to support our clinical trials and to supply drug products to patients once commercialized.
Operational excellence is at the core of all we do at Tryp Therapeutics in our pursuit to provide effective treatments to millions of patients around the world.